Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • FROM THE ANALYST'S COUCH

Demystifying industry–academia collaboration

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Nature Reviews Drug Discovery 18, 743-744 (2019)

doi: https://doi.org/10.1038/d41573-019-00001-2

Acknowledgements

The authors from ETH Zurich would like to acknowledge funding from the Swiss National Science Foundation (grant #146439).

Supplementary Information

  1. 41573_2019_CM16372872_MOESM1_ESM

Competing Interests

A.S., D.E. and H.W. are employees and shareholders of Novartis. G.K. is a former employee and current shareholder of Novartis. Novartis covered travel and data transcription expenses for the authors from ETH Zurich.

Subjects

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links